BICYCLE THERAPEUTICS PLC — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Bicycle Therapeutics reported Q2 2026 net loss of $50.3M (vs. $79.0M in Q2 2025) on cash and equivalents of $510.1M as of June 30, 2026 (down from $628.1M Dec 31, 2025). R&D expenses fell to $41.2M from $71.0M YoY due to workforce reduction and lower clinical program costs. Lead program nuzefatide showed encouraging Phase 1/2 data in urothelial cancer (65% ORR in 26 patients) and Phase 2 enrollment began in pancreatic cancer in April 2026; zelenectide demonstrated 58-62% confirmed ORR in urothelial cancer. Clinical Advisory Board expanded with addition of Thomas Powles.
Why this rating
Moderate event: improved cash position relative to burn ($510M for ~3.7 years at current burn), positive clinical data supporting pipeline, but $118M cash burn in 6 months and no approved products. Represents ordinary clinical-stage pharma progress relative to company's $267M market cap.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.